STOCK TITAN

Repligen (RGEN) director receives 995 RSUs and 2,239 options in equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Repligen Corporation director Carrie Eglinton Manner reported compensation-related equity awards, not open-market trades. She was granted 995 restricted stock units, each representing a contingent right to receive one share of Repligen common stock. She also received stock options for 2,239 shares at an exercise price of $103.38 per share.

The restricted stock units and the stock option award each vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual meeting of shareholders. Following these grants, she holds 5,461 shares of common stock directly and 2,239 stock options.

Positive

  • None.

Negative

  • None.
Insider EGLINTON MANNER CARRIE
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 2,239 $0.00 --
Grant/Award Common Stock 995 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 2,239 shares (Direct, null); Common Stock — 5,461 shares (Direct, null)
Footnotes (1)
  1. Ms. Manner was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Restricted stock units granted 995 units Equity award to director on May 14, 2026
Stock options granted 2,239 options Derivative equity award on May 14, 2026
Option exercise price $103.38 per share Stock Option (Right to Buy) grant
Common shares held after award 5,461 shares Total common stock ownership following grant
Options held after award 2,239 options Total stock options following transaction
Vesting date trigger May 14, 2027 Earlier of this date or next annual meeting
Option expiration May 14, 2036 Expiration date for stock option grant
restricted stock units financial
"Ms. Manner was awarded 995 restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 103.3800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual meeting of the Company's shareholders financial
"on the date of the next annual meeting of the Company's shareholders"
vest in full financial
"Award vests in full on the earlier of May 14, 2027"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EGLINTON MANNER CARRIE

(Last)(First)(Middle)
C/O REPLIGEN CORPORATION
41 SEYON ST., BLDG 1, STE 100

(Street)
WALTHAM MASSACHUSETTS 02453

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REPLIGEN CORP [ RGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/14/2026A995(1)A$0.005,461D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$103.3805/14/2026A2,23905/14/2027(2)05/14/2036Common Stock2,239$0.002,239D
Explanation of Responses:
1. Ms. Manner was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
2. Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
/s/ Jennifer Carmichael (Attorney in Fact)05/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Carrie Eglinton Manner report at Repligen (RGEN)?

Carrie Eglinton Manner reported receiving equity awards from Repligen as compensation, not open-market trades. She was granted 995 restricted stock units and 2,239 stock options, both tied to Repligen common stock, with future vesting based on time and the next shareholder meeting.

How many restricted stock units did Carrie Eglinton Manner receive from Repligen (RGEN)?

She received 995 restricted stock units from Repligen Corporation. Each unit represents a contingent right to one share of Repligen common stock, settling only in shares when vested, and is reported as a non-cash equity award aligned with her role as a director.

What are the key terms of Carrie Eglinton Manner’s Repligen (RGEN) stock option grant?

She was granted options covering 2,239 shares of Repligen common stock at an exercise price of $103.38 per share. The options vest in full on the earlier of May 14, 2027, one year from grant, or the date of Repligen’s next annual shareholder meeting.

When do Carrie Eglinton Manner’s restricted stock units and options in Repligen (RGEN) vest?

Both the 995 restricted stock units and the 2,239 stock options vest in full on the earlier of May 14, 2027, one year from the grant date, or the date of Repligen’s next annual meeting of shareholders, which has not yet been determined by the company.

How many Repligen (RGEN) shares does Carrie Eglinton Manner hold after these awards?

After the reported awards, she directly holds 5,461 shares of Repligen common stock. In addition, she holds stock options for 2,239 underlying shares, providing potential future ownership if the options are exercised after vesting on the specified schedule.

Do the reported Repligen (RGEN) Form 4 transactions involve stock purchases or sales in the market?

No, the transactions are grants of restricted stock units and stock options, not open-market purchases or sales. They represent equity-based compensation awards, with no cash price paid for the units and an exercise price of $103.38 only if the options are exercised later.